United Therapeutics (UTHR) Cash from Investing Activities (2009 - 2026)

United Therapeutics has disclosed Cash from Investing Activities across 18 years of filings, most recently posting $87.5 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities rose 129.18% year-over-year to $87.5 million; the TTM figure through Jun 2026 stood at $744.5 million (up 205.95% YoY), while the FY2025 annual figure was -$551.3 million, down 232.14% from the prior year.
• Cash from Investing Activities came in at $87.5 million for Q2 2026 at United Therapeutics, down from $743.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $743.7 million in Q1 2026 to a low of -$359.2 million in Q1 2022.
• Average Cash from Investing Activities over 5 years is -$46.3 million, with a median of -$144.0 million recorded in 2024.
• Year-over-year, Cash from Investing Activities plunged 5601.59% in 2022 and surged 551.55% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$189.3 million in 2022, then surged by 122.24% to $42.1 million in 2023, then tumbled by 392.64% to -$123.2 million in 2024, then sank by 84.74% to -$227.6 million in 2025, then surged by 138.44% to $87.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $87.5 million in Q2 2026, $743.7 million in Q1 2026, and -$227.6 million in Q4 2025.